COVID-19疫苗接种后心肌炎病例系列
该病例系列调查了以色列国防军人员在COVID-19疫苗接种期间住院的心肌炎病例,发现7例症状始于第二剂Pfizer-BioNTech疫苗后第一周,另1例在第二剂后10天诊断但未纳入。所有患者年轻健康、病情轻微无后遗症,第二剂后一周内心肌炎发生率为5.07/100,000接种者。因报告性质无法确立因果关系,建议临床医生警惕此可能性并进一步研究真实发生率。
要点
- 第二剂Pfizer-BioNTech疫苗后一周内心肌炎发生率为5.07/100,000接种者。
- 所有心肌炎患者均为年轻健康人员,病情轻微且无后遗症。
- 因报告性质无法确立疫苗接种与心肌炎的因果关系。
核心结论
- 观察到COVID-19疫苗接种后心肌炎病例,但无法确立因果关系,需进一步研究真实发生率。
研究设计与样本
- 病例系列:调查以色列国防军在COVID-19疫苗接种期间(2021年12月28日至2021年3月7日)所有住院军事人员的心肌炎诊断。
主要发现
- 共识别8例心肌炎,其中7例症状始于第二剂Pfizer-BioNTech疫苗后第一周,1例在第二剂后10天诊断但未纳入分析。
- 所有患者年轻且一般健康,病情轻微无后遗症。
- 第二剂疫苗后一周内心肌炎发生率为5.07/100,000接种者。
关键数值与推荐
- 心肌炎发生率:第二剂疫苗后一周内5.07/100,000接种者。
临床怎么用
- 临床医生应意识到Pfizer-BioNTech疫苗接种后可能发生心肌炎。
局限性
- 因报告性质无法确立因果关系。
- 真实发生率需进一步调查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There have been reports of myocarditis following COVID-19 vaccination. We surveyed all hospitalized military personnel in the Isareli Defense Forces during the period of the COVID-19 vaccination operation (12/28/2021-3/7/2021) for diagnosed myocarditis. We identified 7 cases of myocarditis with symptoms starting in the first week after the second dose of COVID-19 Pfizer-BioNTech vaccine. One case of myocarditis diagnosed 10 days after the second dose of the vaccine was not included. These 8 cases comprise of all events of myocarditis diagnosed in military personnel during this time period. All patients were young and generally healthy. All had mild disease with no sequalae. The incidence of myocarditis in the week following a second dose of the vaccine was 5.07/100,000 people vaccinated. Due to the nature of this report no causality could be established. Clinicians should be aware of the possibility of myocarditis following Pfizer-BioNTech vaccination. True incidence rates should be further investigated.
引用
- Levin D, Shimon G, Fadlon-Derai M, et al. Myocarditis following COVID-19 vaccination - A case series. Vaccine. 2021. PMID: 34535317. doi:10.1016/j.vaccine.2021.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。